# US 2012/0251628 A1 · Compositions and methods for treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251628 A1
- Document ID: US20120251628A1
- Status: Published application
- Kind: A1
- Application number: 13/436,141
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2011-03-30
- Inventors: Young Joo MIN
- Web page: https://patentgrep.com/patent/US20120251628A1

## CPC

- A61K 33/36: Arsenic; Compounds thereof
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions and methods for treating solid tumors are provided. Intraperitoneal administration of sodium meta arsenite, alone or in combination with an anti-cancer agent, results in tumor necrosis and delayed tumor growth. A particularly effective treatment for colon and rectal cancer is a combination of sodium meta arsenite administered intraperitoneally and irinotecan.

## Claims

### Claim 1

A method of treating a solid tumor in a patient in need thereof comprising intraperitoneally administering to the patient a therapeutically effective amount of sodium meta arsenite and an anti-cancer agent that has a different mechanism of action from intraperitoneally administered sodium meta arsenite.

### Claim 2 (depends on 1)

The method of claim 1 wherein the sodium meta arsenite is administered once a week.

### Claim 3 (depends on 1)

The method of claim 1 wherein the anti-cancer agent is an anti-VEGF agent.

### Claim 4 (depends on 1)

The method of claim 1 wherein the anti-cancer agent is irinotecan.

### Claim 5 (depends on 4)

The method of claim 4 wherein the solid tumor is colon cancer.

### Claim 6 (depends on 5)

The method of claim 5 wherein the solid tumor is colorectal cancer.

### Claim 7 (depends on 1)

The method of claim 1 wherein the sodium meta arsenite and anti-cancer agent are administered separately.

### Claim 8 (depends on 7)

The method of claim 7 wherein the sodium meta arsenite is administered to the patient within 24 to 72 hours of administration of the anti-cancer agent to the patient.

### Claim 9 (depends on 4)

The method of claim 4 further comprising administering radiation to the patient prior to, after or during a treatment regimen with sodium meta arsenite and/or irinotecan.

### Claim 10

A method for treating colon tumor(s) in a subject comprising: (a) intraperitoneally administering to a subject in need thereof a combination of one or more therapeutic doses of sodium meta arsenite and one or more therapeutic doses of irinotecan; (b) monitoring the colon cancer cells and/or the bulk colon cancer tumor size and/or integrity in the subject prior to and/or after administration of a predetermined number of doses of the sodium meta arsenite and/or the irinotecan; and (c) determining whether there is a reduction in the amount of viable colon cancer cells and/or the bulk colon tumor size or integrity of the tumor; and (d) repeating steps (a), (b) and (c) as necessary.

### Claim 11 (depends on 10)

The method of claim 10 wherein the sodium meta arsenite and irinotecan are administered separately.

### Claim 12 (depends on 10)

The method of claim 10 wherein the sodium meta arsenite is administered intermittently.

### Claim 13 (depends on 12)

The method of claim 12 wherein the sodium meta arsenite is administered on a weekly basis.

### Claim 14

A kit for the treatment of a solid tumor comprising one or more dosage units of sodium meta arsenite formulated for intraperitonal injection and one of more dosage units of irinotecan.
